Daily Stock Analysis, CLBS, Caladrius Biosciences Inc, priceseries

Caladrius Biosciences Inc. Daily Stock Analysis
Stock Information
Open
3.31
Close
3.45
High
3.52
Low
3.25
Previous Close
3.43
Daily Price Gain
0.02
YTD High
7.79
YTD High Date
Mar 17, 2017
YTD Low
2.63
YTD Low Date
Nov 2, 2017
YTD Price Change
0.37
YTD Gain
11.98%
52 Week High
7.79
52 Week High Date
Mar 17, 2017
52 Week Low
2.63
52 Week Low Date
Nov 2, 2017
52 Week Price Change
0.12
52 Week Gain
3.60%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 16. 2017
3.07
Dec 4. 2017
3.34
11 Trading Days
8.75%
Link
Company Information
Stock Symbol
CLBS
Exchange
NasdaqCM
Company URL
http://www.caladrius.com
Company Phone
908-842-0100
CEO
David J. Mazzo
Headquarters
New Jersey
Business Address
110 ALLEN ROAD, SECOND FLOOR, BASKING RIDGE, NJ 07920
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000320017
About

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

Description

Caladrius Biosciences, Inc. provides development and manufacturing services to the cell therapy industry in the United States. The company offers process development and clinical manufacturing services for therapeutic candidates in various stages of development. It is also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. Caladrius Biosciences, Inc. has a strategic collaboration with Hitachi Chemical Co. America, Ltd. and Hitachi Chemical Co., Ltd. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.